XORTX Therapeutics (TSXV:XRTX) Change In Receivables : C$0.01 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is XORTX Therapeutics Change In Receivables?

XORTX Therapeutics's change in receivables for the quarter that ended in Mar. 2024 was C$0.04 Mil. It means XORTX Therapeutics's Accounts Receivable declined by C$0.04 Mil from Dec. 2023 to Mar. 2024 .

XORTX Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was C$0.03 Mil. It means XORTX Therapeutics's Accounts Receivable declined by C$0.03 Mil from Dec. 2022 to Dec. 2023 .

XORTX Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2024 was C$0.04 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. XORTX Therapeutics's liquidation value for the three months ended in Mar. 2024 was C$0.41 Mil.

XORTX Therapeutics Change In Receivables Historical Data

The historical data trend for XORTX Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Change In Receivables Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

0.01

-0.04

-0.06

0.03

XORTX Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															0.06	0.01	-0.05	0.01	0.04

XORTX Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.01 Mil.

XORTX Therapeutics (TSXV:XRTX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

XORTX Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.042	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, XORTX Therapeutics's accounts receivable are only considered to be worth 75% of book value:

XORTX Therapeutics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5.191	-	4.817	+	0.75 * 0.042	+	0.5 * 0
=	0.41

XORTX Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (TSXV:XRTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (TSXV:XRTX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

XRTX:USA ANUA:Germany ANUA:Germany

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Executives

Allen Warren Davidoff

Director, Senior Officer